Hematologic Malignancies Market to Reach USD 128.48 Billion by 2032, Driven by Immunotherapy, CAR-T, and Precision Oncology - Credence Research Inc.

Positive

AI Analysis

Summary

Credence Research projects the hematologic malignancies market will reach USD 128.48 billion by 2032, driven by immunotherapy, CAR-T, and precision oncology advances. This is a market research forecast with no company-specific clinical or regulatory developments.

Financial Highlights

Revenue

USD 128.48 Billion

Guidance

2032

Importance:2/10

Sentiment:

0.30

hematologic_malignanciesmarket_researchimmunotherapyCAR-Tprecision_oncologymarket_forecast

Related Companies

$POCI $TOI

Read the original article

Published by PR Newswire Biotech on March 3, 2026 7:36 PM

Read Original